Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Sanofi India Ltd Stock Analysis

Mid Cap
Evaluated by 1972 users | BSE: 500674 | NSE: SANOFI |
Pharmaceuticals & Drugs

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sanofi India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
 Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20TTM
Return on Capital Employed 18%15.25%19.06%15.54%16.93%17.32%16.53%17.76%19.57%22.36%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1,3011,5731,8091,9772,1932,3672,4642,7713,0712,9022,921
Y-o-Y Gr. Rt.-20.9%15%9.3%10.9%7.9%4.1%12.5%10.8%-5.5%-
Adjusted EPS (Rs.) 83.1376.41105.4395.43114.28131.29139.94163.5197.93220.9251.88
Y-o-Y Gr. Rt.--8.1%38%-9.5%19.8%14.9%6.6%16.8%21.1%11.6%-
Book Value per Share (Rs.) 479.67518.02580.3643.67707.3810.65869.91950.221,043.48897.83697.04
Adjusted Net Profit 191176243220263302322377456509580
Net Op. Cash Flow (Rs. Cr.) 205290273265213322435374412611-
Debt to Cash Flow from Ops 0000000000-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Sanofi India Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 9.3%5.8%5.6%-5.5%
Adjusted EPS 11.5%14.1%16.4%11.6%
Book Value per Share 7.24.91.1-14
Share Price 14.6% 12.8% 6.4% -7.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20TTM
Return on Equity (%) 17.9715.1719.0415.5216.9117.2316.4917.7419.5622.3131.59
Operating Profit Margin (%) 19.0619.8322.0117.3420.9722.6121.8622.5521.7324.6727.24
Net Profit Margin (%) 14.7111.1913.4211.111212.7813.0813.5914.8517.5319.86
Debt to Equity 00000000000
Working Capital Days 146109122151149156287379386419167
Cash Conversion Cycle 4341384239503120181378
Loading price chart...
Entity Percentage Holding
Promoters 60.40%
Institutions 28.28%
Non-Institutions 11.33%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanofi India Ltd is a good quality company.

Sanofi India Ltd's earnings have grown by 14.1%, whereas share price has appreciated 12.8% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.

Sanofi India Ltd share price has appreciated 13.2% annually (CAGR) over the past ten years.

Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that Sanofi India Ltd is a good long term investment. However, you need to ensure you buy at a right price to earn good returns.

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.

Business area of the company

The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Products

Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).

Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)

Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)

Milestones

  • 2013: Sanofi India launches Combiflam Plus.
  • 2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
  • 2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
  • 2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
  • 2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
  • 2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
  • 2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
  • 2018: Sanofi receives positive CHMP opinion for dengue vaccine.
  • 2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
  • 2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
  • 2020: Sanofi Completes Acquisition of Synthorx, Inc.
  • 2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
  • 2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback